{"success":true,"data":{"pressRelease":{"id":"181255","rtpr_id":"nGNX2pLhVd-20261027","ticker":"XGN","exchange":"NASDAQ","all_tickers":["XGN"],"title":"Exagen to Announce Third Quarter Financial Results on November 10, 2026","author":"Globe Newswire","published_at":"2026-10-27T13:00:06.462Z","article_body":"CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),\na leading provider of innovative autoimmune testing, will release financial\nresults for the quarter ended September 30, 2026, before the market opens on\nTuesday, November 10, 2026. John Aballi, President and Chief Executive\nOfficer, and Jeff Black, Chief Financial Officer, will host a webcast at 8:00\na.m. ET (5:00 a.m. PT) that morning to review the results.\n\nThe webcast will be available on the Exagen Investor Relations website at\ninvestors.exagen.com\n(https://www.globenewswire.com/Tracker?data=_WVLWHzKY1-laiprlReYYOFyV3YkDxVqtXjR2OeOmlmlIrlAk9037E1Xpol66rdOKauXLteCmaORrF-UD9S_5Bdz-e9wo1fTGxrwnVyb46A=).\nParticipants wishing to join by phone should register in advance using the\nfollowing link for dial-in instructions:\nhttps://register-conf.media-server.com/register/BId7f4a0dc53154d5e84d4eb39ccfa279d.\n\nA replay of the webcast will be available for 12 months via the Exagen\nInvestor Relations website at investors.exagen.com\n(https://www.globenewswire.com/Tracker?data=_WVLWHzKY1-laiprlReYYOFyV3YkDxVqtXjR2OeOmlmfmi_0E-vM11JLE2VK_iEr0ei5hk84jeR-GjKe9vT-dM6Di9B_icYw_hJ3ndmAQbw=)\n\nAbout Exagen Inc.\n\nExagen Inc. (Nasdaq: XGN) is a specialized diagnostics company with an\nautoimmune platform that empowers physicians to make more confident decisions,\nearlier. Its flagship test, AVISE(®) CTD, provides diagnostic clarity in\ncomplex autoimmune conditions such as lupus, rheumatoid arthritis, and\nSjögren's disease. Based in San Diego County, California, Exagen operates\na CLIA-certified, CAP-accredited rheumatology laboratory delivering precise,\ntimely results to physicians and partners across healthcare and\nbiopharma. Through ongoing research and innovation, Exagen is committed to\nadvancing care for autoimmune disease.  \n\nFor more information, visit Exagen.com\n(https://www.globenewswire.com/Tracker?data=0vU05Nnhx9EtGt7H33RT_KOdiXxxK-B48-HdXtpyyvYw4mK6592IZ7y2CvPX6RHBt7qUHF6noporPRu2c9optA==)\nor follow Exagen on LinkedIn\n(https://www.globenewswire.com/Tracker?data=_xpWLLTnSsrdBMlmruBNn_pAMw4Na1mvTb-3XRFToUEtAMCZQHkwvP2wpCnP9VfeYuZmXu1opnMK7pa6O6aC8oMW5MLlR8fw31NCiTtYNFeTqXGNjOX8TQyxMCFsC8RA). \n\nContact\n\nTina Jacobsen, CFA\nExagen Inc.\nir@exagen.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/143bbf1e-1842-476b-a571-9397a997c5d1)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2pLhVd-20261027","title":"Exagen to Announce Third Quarter Financial Results on November 10, 2026","author":"Globe Newswire","ticker":"XGN","created":"2026-10-27T13:00:06.462Z","tickers":["XGN"],"exchange":"NASDAQ","article_body":"CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),\na leading provider of innovative autoimmune testing, will release financial\nresults for the quarter ended September 30, 2026, before the market opens on\nTuesday, November 10, 2026. John Aballi, President and Chief Executive\nOfficer, and Jeff Black, Chief Financial Officer, will host a webcast at 8:00\na.m. ET (5:00 a.m. PT) that morning to review the results.\n\nThe webcast will be available on the Exagen Investor Relations website at\ninvestors.exagen.com\n(https://www.globenewswire.com/Tracker?data=_WVLWHzKY1-laiprlReYYOFyV3YkDxVqtXjR2OeOmlmlIrlAk9037E1Xpol66rdOKauXLteCmaORrF-UD9S_5Bdz-e9wo1fTGxrwnVyb46A=).\nParticipants wishing to join by phone should register in advance using the\nfollowing link for dial-in instructions:\nhttps://register-conf.media-server.com/register/BId7f4a0dc53154d5e84d4eb39ccfa279d.\n\nA replay of the webcast will be available for 12 months via the Exagen\nInvestor Relations website at investors.exagen.com\n(https://www.globenewswire.com/Tracker?data=_WVLWHzKY1-laiprlReYYOFyV3YkDxVqtXjR2OeOmlmfmi_0E-vM11JLE2VK_iEr0ei5hk84jeR-GjKe9vT-dM6Di9B_icYw_hJ3ndmAQbw=)\n\nAbout Exagen Inc.\n\nExagen Inc. (Nasdaq: XGN) is a specialized diagnostics company with an\nautoimmune platform that empowers physicians to make more confident decisions,\nearlier. Its flagship test, AVISE(®) CTD, provides diagnostic clarity in\ncomplex autoimmune conditions such as lupus, rheumatoid arthritis, and\nSjögren's disease. Based in San Diego County, California, Exagen operates\na CLIA-certified, CAP-accredited rheumatology laboratory delivering precise,\ntimely results to physicians and partners across healthcare and\nbiopharma. Through ongoing research and innovation, Exagen is committed to\nadvancing care for autoimmune disease.  \n\nFor more information, visit Exagen.com\n(https://www.globenewswire.com/Tracker?data=0vU05Nnhx9EtGt7H33RT_KOdiXxxK-B48-HdXtpyyvYw4mK6592IZ7y2CvPX6RHBt7qUHF6noporPRu2c9optA==)\nor follow Exagen on LinkedIn\n(https://www.globenewswire.com/Tracker?data=_xpWLLTnSsrdBMlmruBNn_pAMw4Na1mvTb-3XRFToUEtAMCZQHkwvP2wpCnP9VfeYuZmXu1opnMK7pa6O6aC8oMW5MLlR8fw31NCiTtYNFeTqXGNjOX8TQyxMCFsC8RA). \n\nContact\n\nTina Jacobsen, CFA\nExagen Inc.\nir@exagen.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/143bbf1e-1842-476b-a571-9397a997c5d1)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-27T13:00:06.544665954Z","server_sent_at_ms":1793106006544},"received_at":"2026-10-27T13:00:06.625Z","source_url":null},"analysis":{"id":"169056","press_release_id":"181255","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Exagen will release Q3 2026 financial results for the quarter ended September 30, 2026, before market open on Tuesday, November 10, 2026.\n\nCEO John Aballi and CFO Jeff Black will host a webcast at 8:00 a.m. ET that morning, with a replay available for 12 months on the investor relations site.\n\nNo financial figures or guidance were included in this scheduling notice.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar item only -- set reminder for XGN Q3 results on November 10; no action until figures are released."},"keyFigures":{},"namedEntities":{"people":[{"name":"John Aballi","role":"President and CEO"},{"name":"Jeff Black","role":"CFO"},{"name":"Tina Jacobsen, CFA","role":"Investor relations contact"}],"products":["AVISE CTD"],"companies":[{"name":"Exagen Inc.","ticker":"XGN"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Earnings-date and webcast notice with no results or figures disclosed. Purely administrative scheduling announcement."},"tickerRelevance":{"others":[],"primary":"XGN"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"earnings-date-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Exagen will release Q3 2026 financial results for the quarter ended September 30, 2026, before market open on Tuesday, November 10, 2026.\n\nCEO John Aballi and CFO Jeff Black will host a webcast at 8:00 a.m. ET that morning, with a replay available for 12 months on the investor relations site.\n\nNo financial figures or guidance were included in this scheduling notice.","key_figures":{},"named_entities":{"people":[{"name":"John Aballi","role":"President and CEO"},{"name":"Jeff Black","role":"CFO"},{"name":"Tina Jacobsen, CFA","role":"Investor relations contact"}],"products":["AVISE CTD"],"companies":[{"name":"Exagen Inc.","ticker":"XGN"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-27T13:00:28.804Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"earnings-date-notice","issuerAuthored":true}},"durationMs":3727,"modelName":"glm-5.3-flashx"}}